Emcon 1

Description

Indication
Contraception, Emergency contraception, Menopausal hormone replacement therapy, Menorrhagia,
Administration
May be taken with or without food.
Adult Dose
Oral Emergency contraception Adult: 1.5 mg as soon as possible or within 72 hr of coitus. Alternatively, 750 mcg as soon as possible or within 72 hr of coitus followed by a 2nd dose 12 hr later. Most effective if taken as soon as possible after unprotected intercourse Menopausal hormone replacement therapy Adult: As progestogenic component: 75-250 mcg for 10-12 days of a 28-day cycle. Contraception Adult: Monotherapy: 30 or 37.5 mcg daily.
Contraindication
Pregnancy, undiagnosed vaginal bleeding, severe arterial disease; liver adenoma, porphyria; after recent evacuation of hydatidiform mole; history of breast cancer; hepatic impairment.
Mode of Action
Levonorgestrel, a nortestosterone derivative, is an active isomer of norgestrel. It is a potent inhibitor of ovulation and has androgenic activity.
Precaution
Sex-steroid dependent cancer, past ectopic pregnancy, malabsorption syndromes, functional ovarian cysts, active liver disease, recurrent cholestatic jaundice, history of jaundice in pregnancy, CV or renal impairment, DM, asthma, epilepsy, migraine, conditions aggravated by fluid retention, depression and thromboembolism (high doses); lactation.
Side Effect
>10% Headache (12%),Acne (15%),Ovarian cysts (13%),Enlarged follicles (12%),Amenorrhea (1-12%),Abdominal pain (12%),Uterine/vaginal bleeding alterations (52%),Intermenstrual bleeding/spotting (23%),Vulvovaginitis (20%),Ectopic pregnancy (≤50%) 1-10% Depression (4%),Migraine (2%),Alopecia (1%),Dysmenorrhea (9%),Menorrhagia (6%),Breast tenderness (3-9%),Pelvic pain (6%),Leukorrhea (5%),Vaginal discharge (4%),Pelvic infection (1%) <1% Angioedema,Cervical perforation,Failed insertion,Sepsis,Uterine bleeding,Device breakage Potentially Fatal: Thrombocytopenia, stroke. Interaction Reduced efficacy with enzyme-inducing drugs; aminoglutethimide. May inhibit ciclosporin metabolism.